MHCclassI抗体;MHCclassI Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

Major histocompatibility complex (MHC) class I molecules are cell surface proteins critical for adaptive immunity, present in nearly all nucleated vertebrate cells. They bind intracellularly processed peptide antigens (typically 8-11 amino acids) and present them to CD8+ cytotoxic T lymphocytes (CTLs), enabling immune surveillance against infected or malignant cells. Structurally, MHC class I consists of a polymorphic α-chain (encoded by HLA-A, -B, or -C genes in humans) non-covalently linked to β2-microglobulin. The α-chain forms a peptide-binding groove, with polymorphism determining antigen-binding specificity and immune diversity across individuals.

Antibodies targeting MHC class I (anti-HLA class I in humans) have significant clinical and research implications. They are widely used in transplantation to assess donor-recipient compatibility, as mismatched MHC I can trigger graft rejection. These antibodies also serve as diagnostic tools in autoimmune diseases (e.g., rheumatoid arthritis) and viral infections (e.g., HIV), where altered MHC I expression may impair immune recognition. In cancer biology, reduced MHC I expression – detectable via specific antibodies – correlates with tumor immune evasion. Therapeutic anti-MHC I antibodies are explored for modulating immune responses, though their use risks unintended immunosuppression. Challenges persist in distinguishing pathogenic from benign antibodies and interpreting cross-reactivity due to MHC I's extensive polymorphism.